IMpassion031: Atezolizumab & Early TNBC – Final Results
Researchers are increasingly disclosing financial ties to pharmaceutical companies,a crucial step for maintaining research integrity. This report details the diverse conflicts of interest revealed by numerous individuals involved in medical studies, including speakers fees, advisory roles, and research grants from various pharma firms. The goal is clear: ensuring transparency of potential competing interests using a primary_keyword such as “financial disclosures” for unbiased research. News Directory 3 keeps you abreast of the latest developments. Understand how these disclosures impact the credibility of the findings and patient care.Discover what’s next.
Competing Interests Disclosed in Pharmaceutical Research
Numerous researchers involved in medical studies have disclosed financial and advisory relationships with pharmaceutical companies. These disclosures, highlighting potential competing interests, are a standard practice to ensure transparency and maintain the integrity of research findings.
E.A.M. reported compensated advisory board service for AstraZeneca, BioNTech, Merck, and Moderna. Additionally, E.A.M. noted uncompensated roles on steering committees for Bristol Myers Squibb and Roche/Genentech,along with speaker fees and travel support from Merck Sharp and Dohme (MSD). Institutional research support was provided by Roche/Genentech and Gilead. Research funding also came from Susan Komen for the Cure.
Z.J.A., E.S.-K., L.M., and S.Y.C. are either current or former employees of Genentech, holding shares in Roche. N.H. reported consulting fees from Gilead, Sandoz, and Seagen, along with speaker honoraria from Amgen, AstraZeneca, Daiichi Sankyo, gilead, Eli Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, and Seagen. H.Z. declared honoraria for advisory roles with Roche/Genentech.
S.S.reported speaker honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho, Ono, Nippon Kayaku, Gilead, and Exact Sciences. Research grants were received (by institution) from Taiho,Eisai,Chugai,Takeda,MSD,AstraZeneca,Daiichi Sankyo,Gilead,Eli Lilly,and Sanofi.Advisory roles included Chugai/roche,AstraZeneca,Eli lilly,Pfizer,Kyowa Kirin,Daiichi Sankyo,and MSD.
K.H.J. reported advisory roles for AstraZeneca, Bixink, Everest Medicine, MSD, Novartis, Pfizer, Roche, Takeda Pharmaceuticals, and Daiichi Sankyo. A.K. declared advisory roles for Roche, Novartis, Pfizer, Amgen, Daiichi, and MSD, along with a research grant from the German Breast Group. J.S.reported research grants (to institution) from MSD, Roche, Novartis, AstraZeneca, Lilly, Pfizer, GSK, Daiichi Sankyo, Sanofi, Boehringer Ingelheim, and Seagen.
H.I. reported advisory roles for Chugai, Daiichi Sankyo, AstraZeneca, Lilly, and Sanofi, along with speaker honoraria from Pfizer and Taiho. M.L.T. reported research grants (to institution) from Arvinas, AstraZeneca, Bayer, Blueprint Medicines, Genentech/Roche, GlaxoSmithKline, Hummingbird Biosciences, Merck, Novartis, OncoSec Medical, and Pfizer. Advisory roles included AstraZeneca, blueprint Medicines, Daiichi sankyo, Genentech/Roche, Gilead, GlaxoSmithKline, G1 Therapeutics, Guardant, Merck, Natera, Novartis, Pfizer, RefleXion, Replicate, and Sanofi.
C.F. reported honoraria from Pfizer,Bayer,Novartis,AstraZeneca,Merck,Roche Canada,Knights Therapeutics,and Janssen Oncology. Research funding (to institution) came from Astellas Pharma, AstraZeneca, lilly, Merck, Novartis, Roche/Genentech, Pfizer, Janssen Oncology, Zymeworks, Seattle Genetics, and Sermonix Pharmaceuticals. K.P. reported honoraria (to institution) for advisory roles from AstraZeneca, Novartis, Roche, Vifor Pharma, Eli Lilly, Pierre Fabre, McCann Health, Roularta, Teva, Gilead Sciences, Pfizer, and MSD.
A.Q., M.D., and M.L.-H. are employees of F. Hoffmann-La Roche and hold shares in Roche. Y.X. is an employee of Hoffmann-La Roche Ltd and holds shares in Roche. C.H.B. reported research funding (to institution) from numerous pharmaceutical companies and clinical research organizations, along with ownership in Tummi and MEDSir. R.H. declared no competing interests.
What’s next
Continued vigilance and transparent reporting of competing interests remain essential to upholding the credibility of pharmaceutical research and ensuring patient safety.